These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7340986)

  • 1. Delayed recovery of peripheral blood cell numbers after adjuvant cytotoxic chemotherapy for stage II breast cancer.
    Goodyear MD; Mackay IR; Russell IS
    Cancer Chemother Pharmacol; 1981; 7(1):37-40. PubMed ID: 7340986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphalan in breast cancer.
    Mackay IR; Goodyear MD; Riglar C; Penschow J; Whittingham S; Russell IS; Kitchen PR; Collins JP
    Cancer; 1984 Jun; 53(12):2619-27. PubMed ID: 6609758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer.
    Marks LB; Rosner GL; Prosnitz LR; Ross M; Vredenburgh JJ; Peters WP
    Cancer; 1994 Dec; 74(11):2964-71. PubMed ID: 7954260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable factors in the adjuvant therapy of breast cancer.
    Carpenter JT; Maddox WA; Laws HL; Wirtschafter DD; Soong SJ
    Cancer; 1982 Jul; 50(1):18-23. PubMed ID: 7044517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
    Raina V; Sharma A; Kumar R; Bhargava M
    Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy in breast cancer--a multicenter trial.
    Faber P; Jesdinsky H
    Cancer Treat Rev; 1979 Jun; 6 Suppl():75-8. PubMed ID: 387230
    [No Abstract]   [Full Text] [Related]  

  • 10. Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
    Hurria A; Brogan K; Panageas KS; Jakubowski A; Zauderer M; Pearce C; Norton L; Howard J; Hudis C
    Drugs Aging; 2005; 22(8):709-15. PubMed ID: 16060720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation.
    Fisher ER; Redmond C; Fisher B
    Cancer; 1983 Jan; 51(2):181-91. PubMed ID: 6821810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer.
    Danforth DN; Lippman ME; McDonald H; Bader J; Egan E; Lampert M; Steinberg SM; Swain SM
    Am Surg; 1990 Jan; 56(1):6-11. PubMed ID: 2153011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study over a 5-year period of adjuvant chemotherapy after mastectomy for breast cancer.
    Fennelly JJ; Cantwell B; Jones M
    Ir Med J; 1981 Feb; 74(2):46-8. PubMed ID: 7228618
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
    Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
    Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.
    Gianni AM; Siena S; Bregni M; Di Nicola M; Orefice S; Cusumano F; Salvadori B; Luini A; Greco M; Zucali R; Rilke F; Zambetti M; Valagussa P; Bonadonna G
    J Clin Oncol; 1997 Jun; 15(6):2312-21. PubMed ID: 9196145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours.
    Nieboer P; de Vries EG; Mulder NH; Sleijfer DT; Willemse PH; Hospers GA; Gietema JA; Sluiter WJ; van Der Graaf WT
    Bone Marrow Transplant; 2001 May; 27(9):959-66. PubMed ID: 11436106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer.
    Mackay IR; Goodyear MD; Riglar C; Penschow J
    Cancer Immunol Immunother; 1983; 16(2):98-100. PubMed ID: 6420047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer.
    Cooper MR; Rhyne AL; Muss HB; Ferree C; Richards F; White DR; Stuart JJ; Jackson DV; Howard V; Shore A; Spurr CL
    Cancer; 1981 Jun; 47(12):2833-9. PubMed ID: 7020917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.